RLYB116 is a novel, innovative, once-weekly, small volume, subcutaneously injected C5 inhibitor designed to meet patient demand for a convenient, self-administered at-home solution. RLYB116 is an antibody mimetic fusion protein composed of two linked components: 

• An Affibody® molecule with high affinity for C5, thereby inhibiting terminal complement activation, and 

• Albumod™ technology that enables binding to serum albumin for the potential of an extended plasma half-life and broad tissue distribution